Mallinckrodt to Present at J.P. Morgan Healthcare Conference January 12

Mallinckrodt plc (NYSE: MNK), a global specialty biopharmaceutical company, will present at the 33rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis on Union Square in San Francisco on Monday, January 12, 2015. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will represent the company in a session scheduled to begin at 3 p.m. Pacific/6 p.m. Eastern.

Individuals who cannot attend the meeting in person can find webcast information on Mallinckrodt’s Investor Relations website or at: http://mallinckrodt.com/investor_relations. A replay will also be available following the meeting.

ABOUT MALLINCKRODT

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has more than 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

MallinckrodtRhonda Sciarra, 314-654-8618Manager, [e-mail] Fischer, 314-654-3318Senior Vice President, [e-mail] Moten, 314-654-6650Vice President, Investor [e-mail]